Chief Scientific Officer
Michael Agrez MBBS MS PhD FRCS FRACS
Michael’s career background is a combination of basic science research and clinical practice as a colorectal surgeon that commenced while at the Mayo Clinic. Subsequently, during his 30-year tenure with The University of Newcastle, Australia, he has published numerous articles in peer-reviewed journals that cover aspects of epidemiology, cancer screening, molecular biology, biochemistry and immunology. During the past 10 years Michael has developed immunomodulating peptides that have potential to suppress cancer growth, autoimmune responses, endometriosis, and radiation-induced DNA damage.
A/g CEO
Stephen Parker, Business Operations
Stephen has worked across biotechnology product development and commercialisation for more than 35 years. Prior to joining InterK, he patented and successfully commercialised a range of surgical devices. He has broad experience in business operations, product development, and strategic coordination relevant to the advancement of InterK’s peptide therapeutics program. He holds a Bachelor of Arts from the University of Sydney in Government and International Relations and in Japanese studies.
Share this page